Good Harbor Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Good Harbor Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$226K	Sell	3,922 -789	-17%	-$45.3K	0.22%	78
2026 Q1	$286K	Hold	4,711	–	–	0.31%	64
2025 Q4	$254K	Buy	+4,711	New	+$227K	0.3%	65

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Good Harbor Advisors's BMY Position: Q2 2026 in Review

Good Harbor Advisors reduced its Bristol-Myers Squibb (BMY) stake by 17% in Q2 2026, selling an estimated $45.3K and leaving 3,922 shares worth $226K. The position accounts for 0.22% of the portfolio, ranked #78.

Good Harbor Advisors first reported a position in BMY in Q4 2025 and has held it in 3 quarters since. The position peaked at $286K in Q1 2026. 2,503 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Good Harbor Advisors held 3,922 shares of Bristol-Myers Squibb worth $226K as of Q2 2026.
Good Harbor Advisors sold 789 Bristol-Myers Squibb shares in Q2 2026, an estimated $45.3K.
Bristol-Myers Squibb made up 0.22% of Good Harbor Advisors's portfolio in Q2 2026, its #78 holding.
Good Harbor Advisors first reported a position in Bristol-Myers Squibb in Q4 2025 and has held it in 3 quarters since.
Good Harbor Advisors's Bristol-Myers Squibb position peaked at $286K in Q1 2026.
2,503 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Good Harbor Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.